Related Experiment Videos
Coadministration of vigabatrin and valproate in children with refractory epilepsy
J A Armijo1, R Arteaga, E M Valdizán
1Clinical Pharmacology Service, M. de Valdecilla University Hospital, University of Cantabria School of Medicine, Santander, Spain.
Insights
Adding vigabatrin (GVG) to antiepileptic drug regimens significantly reduced seizure frequency in children with refractory epilepsy. This combination therapy, particularly with sodium valproate (VPA), proved effective without altering drug concentrations.
Area of Science:
- Pediatric Neurology
- Pharmacology
- Epilepsy Research
Background:
- Refractory epilepsy in children poses significant treatment challenges.
- Understanding the efficacy of add-on antiepileptic therapies is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the effects of add-on vigabatrin (GVG) in pediatric patients with refractory epilepsy.
- To assess the impact of GVG on seizure frequency, GABA-T activity, and drug plasma concentrations, with or without concurrent sodium valproate (VPA) therapy.
Main Methods:
- A study involving 16 children with refractory epilepsy.
- Vigabatrin was added to existing antiepileptic regimens, with half including sodium valproate.
- Seizure frequency, platelet GABA-T activity, and plasma concentrations of GVG and VPA were monitored.
Main Results:
- Add-on GVG significantly reduced seizure frequency in both VPA and non-VPA groups.
- GVG demonstrated greater seizure reduction and GABA-T inhibition in patients receiving VPA.
- No significant changes in steady-state plasma concentrations of GVG or VPA were observed.
Conclusions:
- Coadministration of vigabatrin with valproate is effective in reducing seizures in refractory epileptic children.
- This combination therapy does not affect the steady-state plasma concentrations of either drug, suggesting potential clinical utility.
Abstract:
The effects of adding vigabatrin (GVG) to the antiepileptic regimens of 16 children with refractory epilepsy have been studied. One-half of the regimens included sodium valproate (VPA). Parameters studied were seizure reduction, platelet GABA-T activity, and steady-state plasma concentrations (CSS) of GVG and VPA. Add-on GVG reduced the seizure frequency both in patients receiving VPA (from 42.9 to 4.5 seizures/month, p < 0.01) and in those without VPA (from 60.0 to 31.7 seizures/month, p < 0.05). GVG also reduced GABA-T activity in both groups (from 19.4 to 5.4, p < 0.001 and from 8.3 to 4.5 pmol/min/mg of protein, p < 0.05, respectively). Seizure reduction and GABA-T inhibition were greater in patients taking VPA than in those who were not. In patients receiving VPA, no significant changes were observed in VPA CSS values before and after the addition of GVG. On the other hand, no differences were found in GVG CSS values between patients with and without VPA. It is concluded that the coadministration of GVG to valproate reduces the frequency of seizures in refractory epileptic children and does not affect the steady-state plasma concentrations of either drug. Therefore, their association could be useful in clinical practice.